Influence of gastrointestinal events on treatment of osteoporosis in Asia-Pacific women: Perspectives from physicians in the MUSIC OS-AP study.
Identifieur interne : 000A18 ( Main/Exploration ); précédent : 000A17; suivant : 000A19Influence of gastrointestinal events on treatment of osteoporosis in Asia-Pacific women: Perspectives from physicians in the MUSIC OS-AP study.
Auteurs : A. Modi [États-Unis] ; P R Ebeling [Australie] ; M S Lee [Taïwan] ; Y K Min [Corée du Sud] ; A. Mithal [Inde] ; X. Yang [États-Unis] ; S. Baidya [Australie] ; S. Sen [États-Unis] ; S. Sajjan [États-Unis]Source :
- Bone reports [ 2352-1872 ] ; 2017.
Abstract
BACKGROUND
The objectives of the physician survey component of the MUSIC OS-AP study were to describe physicians' approaches to treatment of women with postmenopausal osteoporosis and to understand the influence of gastrointestinal (GI) events on treatment in clinical practice.
METHODS
Physicians were recruited from 5 Asia-Pacific countries. Questionnaires collected information about physicians' standard practices for treatment of patients with osteoporosis, as well as their perspectives on the influence of GI events on osteoporosis treatment approaches.
RESULTS
A total of 59 physicians participated in the study. The most frequently prescribed or recommended treatments were vitamin D (84% of patients), calcium (82%), and oral bisphosphonates (59%). When choosing a medication for treatment-naïve patients, GI sensitivity was often or always a factor for 79% of physicians. Among physicians not prescribing pharmacologic treatment, a mean of 18% of non-prescriptions were due to GI sensitivity. For patients with pre-existing GI conditions, physicians most frequently ranked use of non-oral osteoporosis medication as the first treatment strategy (47%), followed by co-prescription with a proton pump inhibitor or other gastro-protective agent (31%). For patients developing GI symptoms after starting pharmacologic treatment, the most frequently first-ranked management strategy was to check if patients were taking their osteoporosis medication correctly as prescribed (64%), followed by temporary discontinuation of the medication (i.e., a drug holiday) until GI events have resolved (31%) and co-prescription with a proton pump inhibitor or other gastroprotective agent (24%).
CONCLUSIONS
These results suggest that GI events influence the prescribing practices of physicians in the Asia-Pacific region and sometimes result in non-treatment of women with osteoporosis.
DOI: 10.1016/j.bonr.2017.09.003
PubMed: 29062864
PubMed Central: PMC5650647
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Influence of gastrointestinal events on treatment of osteoporosis in Asia-Pacific women: Perspectives from physicians in the MUSIC OS-AP study.</title><author><name sortKey="Modi, A" sort="Modi, A" uniqKey="Modi A" first="A" last="Modi">A. Modi</name><affiliation wicri:level="2"><nlm:affiliation>Center for Observational and Real-World Evidence, Merck & Co., Inc., Kenilworth, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Center for Observational and Real-World Evidence, Merck & Co., Inc., Kenilworth, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Ebeling, P R" sort="Ebeling, P R" uniqKey="Ebeling P" first="P R" last="Ebeling">P R Ebeling</name><affiliation wicri:level="1"><nlm:affiliation>Monash University, Clayton, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Monash University, Clayton</wicri:regionArea><wicri:noRegion>Clayton</wicri:noRegion></affiliation></author><author><name sortKey="Lee, M S" sort="Lee, M S" uniqKey="Lee M" first="M S" last="Lee">M S Lee</name><affiliation wicri:level="1"><nlm:affiliation>Kaohisung Chang Gung Memorial Hospital, Chang Gung University, Taiwan.</nlm:affiliation><country xml:lang="fr">Taïwan</country><wicri:regionArea>Kaohisung Chang Gung Memorial Hospital, Chang Gung University</wicri:regionArea><wicri:noRegion>Chang Gung University</wicri:noRegion></affiliation></author><author><name sortKey="Min, Y K" sort="Min, Y K" uniqKey="Min Y" first="Y K" last="Min">Y K Min</name><affiliation wicri:level="3"><nlm:affiliation>Division of Endocrinology and Metabolism, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Division of Endocrinology and Metabolism, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul</wicri:regionArea><placeName><settlement type="city">Séoul</settlement><region type="capital">Région capitale de Séoul</region></placeName></affiliation></author><author><name sortKey="Mithal, A" sort="Mithal, A" uniqKey="Mithal A" first="A" last="Mithal">A. Mithal</name><affiliation wicri:level="1"><nlm:affiliation>Medanta the Medicity, Gurgaon, Haryana, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Medanta the Medicity, Gurgaon, Haryana</wicri:regionArea><wicri:noRegion>Haryana</wicri:noRegion></affiliation></author><author><name sortKey="Yang, X" sort="Yang, X" uniqKey="Yang X" first="X" last="Yang">X. Yang</name><affiliation wicri:level="2"><nlm:affiliation>Center for Observational and Real-World Evidence, Merck & Co., Inc., Kenilworth, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Center for Observational and Real-World Evidence, Merck & Co., Inc., Kenilworth, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Baidya, S" sort="Baidya, S" uniqKey="Baidya S" first="S" last="Baidya">S. Baidya</name><affiliation wicri:level="1"><nlm:affiliation>Optum, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Optum</wicri:regionArea></affiliation></author><author><name sortKey="Sen, S" sort="Sen, S" uniqKey="Sen S" first="S" last="Sen">S. Sen</name><affiliation wicri:level="2"><nlm:affiliation>Center for Observational and Real-World Evidence, Merck & Co., Inc., Kenilworth, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Center for Observational and Real-World Evidence, Merck & Co., Inc., Kenilworth, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Sajjan, S" sort="Sajjan, S" uniqKey="Sajjan S" first="S" last="Sajjan">S. Sajjan</name><affiliation wicri:level="2"><nlm:affiliation>Center for Observational and Real-World Evidence, Merck & Co., Inc., Kenilworth, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Center for Observational and Real-World Evidence, Merck & Co., Inc., Kenilworth, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:29062864</idno><idno type="pmid">29062864</idno><idno type="doi">10.1016/j.bonr.2017.09.003</idno><idno type="pmc">PMC5650647</idno><idno type="wicri:Area/Main/Corpus">000905</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000905</idno><idno type="wicri:Area/Main/Curation">000905</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000905</idno><idno type="wicri:Area/Main/Exploration">000905</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Influence of gastrointestinal events on treatment of osteoporosis in Asia-Pacific women: Perspectives from physicians in the MUSIC OS-AP study.</title><author><name sortKey="Modi, A" sort="Modi, A" uniqKey="Modi A" first="A" last="Modi">A. Modi</name><affiliation wicri:level="2"><nlm:affiliation>Center for Observational and Real-World Evidence, Merck & Co., Inc., Kenilworth, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Center for Observational and Real-World Evidence, Merck & Co., Inc., Kenilworth, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Ebeling, P R" sort="Ebeling, P R" uniqKey="Ebeling P" first="P R" last="Ebeling">P R Ebeling</name><affiliation wicri:level="1"><nlm:affiliation>Monash University, Clayton, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Monash University, Clayton</wicri:regionArea><wicri:noRegion>Clayton</wicri:noRegion></affiliation></author><author><name sortKey="Lee, M S" sort="Lee, M S" uniqKey="Lee M" first="M S" last="Lee">M S Lee</name><affiliation wicri:level="1"><nlm:affiliation>Kaohisung Chang Gung Memorial Hospital, Chang Gung University, Taiwan.</nlm:affiliation><country xml:lang="fr">Taïwan</country><wicri:regionArea>Kaohisung Chang Gung Memorial Hospital, Chang Gung University</wicri:regionArea><wicri:noRegion>Chang Gung University</wicri:noRegion></affiliation></author><author><name sortKey="Min, Y K" sort="Min, Y K" uniqKey="Min Y" first="Y K" last="Min">Y K Min</name><affiliation wicri:level="3"><nlm:affiliation>Division of Endocrinology and Metabolism, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Division of Endocrinology and Metabolism, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul</wicri:regionArea><placeName><settlement type="city">Séoul</settlement><region type="capital">Région capitale de Séoul</region></placeName></affiliation></author><author><name sortKey="Mithal, A" sort="Mithal, A" uniqKey="Mithal A" first="A" last="Mithal">A. Mithal</name><affiliation wicri:level="1"><nlm:affiliation>Medanta the Medicity, Gurgaon, Haryana, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Medanta the Medicity, Gurgaon, Haryana</wicri:regionArea><wicri:noRegion>Haryana</wicri:noRegion></affiliation></author><author><name sortKey="Yang, X" sort="Yang, X" uniqKey="Yang X" first="X" last="Yang">X. Yang</name><affiliation wicri:level="2"><nlm:affiliation>Center for Observational and Real-World Evidence, Merck & Co., Inc., Kenilworth, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Center for Observational and Real-World Evidence, Merck & Co., Inc., Kenilworth, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Baidya, S" sort="Baidya, S" uniqKey="Baidya S" first="S" last="Baidya">S. Baidya</name><affiliation wicri:level="1"><nlm:affiliation>Optum, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Optum</wicri:regionArea></affiliation></author><author><name sortKey="Sen, S" sort="Sen, S" uniqKey="Sen S" first="S" last="Sen">S. Sen</name><affiliation wicri:level="2"><nlm:affiliation>Center for Observational and Real-World Evidence, Merck & Co., Inc., Kenilworth, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Center for Observational and Real-World Evidence, Merck & Co., Inc., Kenilworth, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Sajjan, S" sort="Sajjan, S" uniqKey="Sajjan S" first="S" last="Sajjan">S. Sajjan</name><affiliation wicri:level="2"><nlm:affiliation>Center for Observational and Real-World Evidence, Merck & Co., Inc., Kenilworth, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Center for Observational and Real-World Evidence, Merck & Co., Inc., Kenilworth, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author></analytic><series><title level="j">Bone reports</title><idno type="ISSN">2352-1872</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b></p><p>The objectives of the physician survey component of the MUSIC OS-AP study were to describe physicians' approaches to treatment of women with postmenopausal osteoporosis and to understand the influence of gastrointestinal (GI) events on treatment in clinical practice.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>Physicians were recruited from 5 Asia-Pacific countries. Questionnaires collected information about physicians' standard practices for treatment of patients with osteoporosis, as well as their perspectives on the influence of GI events on osteoporosis treatment approaches.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>A total of 59 physicians participated in the study. The most frequently prescribed or recommended treatments were vitamin D (84% of patients), calcium (82%), and oral bisphosphonates (59%). When choosing a medication for treatment-naïve patients, GI sensitivity was often or always a factor for 79% of physicians. Among physicians not prescribing pharmacologic treatment, a mean of 18% of non-prescriptions were due to GI sensitivity. For patients with pre-existing GI conditions, physicians most frequently ranked use of non-oral osteoporosis medication as the first treatment strategy (47%), followed by co-prescription with a proton pump inhibitor or other gastro-protective agent (31%). For patients developing GI symptoms after starting pharmacologic treatment, the most frequently first-ranked management strategy was to check if patients were taking their osteoporosis medication correctly as prescribed (64%), followed by temporary discontinuation of the medication (i.e., a drug holiday) until GI events have resolved (31%) and co-prescription with a proton pump inhibitor or other gastroprotective agent (24%).</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b></p><p>These results suggest that GI events influence the prescribing practices of physicians in the Asia-Pacific region and sometimes result in non-treatment of women with osteoporosis.</p></div></front></TEI><pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">29062864</PMID><DateRevised><Year>2020</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2352-1872</ISSN><JournalIssue CitedMedium="Print"><Volume>7</Volume><PubDate><Year>2017</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Bone reports</Title><ISOAbbreviation>Bone Rep</ISOAbbreviation></Journal><ArticleTitle>Influence of gastrointestinal events on treatment of osteoporosis in Asia-Pacific women: Perspectives from physicians in the MUSIC OS-AP study.</ArticleTitle><Pagination><MedlinePgn>108-113</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bonr.2017.09.003</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The objectives of the physician survey component of the MUSIC OS-AP study were to describe physicians' approaches to treatment of women with postmenopausal osteoporosis and to understand the influence of gastrointestinal (GI) events on treatment in clinical practice.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Physicians were recruited from 5 Asia-Pacific countries. Questionnaires collected information about physicians' standard practices for treatment of patients with osteoporosis, as well as their perspectives on the influence of GI events on osteoporosis treatment approaches.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 59 physicians participated in the study. The most frequently prescribed or recommended treatments were vitamin D (84% of patients), calcium (82%), and oral bisphosphonates (59%). When choosing a medication for treatment-naïve patients, GI sensitivity was often or always a factor for 79% of physicians. Among physicians not prescribing pharmacologic treatment, a mean of 18% of non-prescriptions were due to GI sensitivity. For patients with pre-existing GI conditions, physicians most frequently ranked use of non-oral osteoporosis medication as the first treatment strategy (47%), followed by co-prescription with a proton pump inhibitor or other gastro-protective agent (31%). For patients developing GI symptoms after starting pharmacologic treatment, the most frequently first-ranked management strategy was to check if patients were taking their osteoporosis medication correctly as prescribed (64%), followed by temporary discontinuation of the medication (i.e., a drug holiday) until GI events have resolved (31%) and co-prescription with a proton pump inhibitor or other gastroprotective agent (24%).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These results suggest that GI events influence the prescribing practices of physicians in the Asia-Pacific region and sometimes result in non-treatment of women with osteoporosis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Modi</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Center for Observational and Real-World Evidence, Merck & Co., Inc., Kenilworth, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ebeling</LastName><ForeName>P R</ForeName><Initials>PR</Initials><AffiliationInfo><Affiliation>Monash University, Clayton, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>M S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Kaohisung Chang Gung Memorial Hospital, Chang Gung University, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Min</LastName><ForeName>Y K</ForeName><Initials>YK</Initials><AffiliationInfo><Affiliation>Division of Endocrinology and Metabolism, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mithal</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Medanta the Medicity, Gurgaon, Haryana, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>X</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Center for Observational and Real-World Evidence, Merck & Co., Inc., Kenilworth, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baidya</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Optum, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sen</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center for Observational and Real-World Evidence, Merck & Co., Inc., Kenilworth, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sajjan</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center for Observational and Real-World Evidence, Merck & Co., Inc., Kenilworth, NJ, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>09</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Bone Rep</MedlineTA><NlmUniqueID>101646176</NlmUniqueID><ISSNLinking>2352-1872</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Asia</Keyword><Keyword MajorTopicYN="N">Australia</Keyword><Keyword MajorTopicYN="N">BMD, bone mineral density</Keyword><Keyword MajorTopicYN="N">GI, gastrointestinal</Keyword><Keyword MajorTopicYN="N">Gastrointestinal diseases</Keyword><Keyword MajorTopicYN="N">MUSIC, medication use patterns, treatment satisfaction, and inadequate control of osteoporosis study</Keyword><Keyword MajorTopicYN="N">Osteoporosis, postmenopausal</Keyword><Keyword MajorTopicYN="N">Osteoporosis/drug therapy</Keyword><Keyword MajorTopicYN="N">Practice patterns, physicians'</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>05</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>09</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>09</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>10</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>10</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>10</Month><Day>25</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29062864</ArticleId><ArticleId IdType="doi">10.1016/j.bonr.2017.09.003</ArticleId><ArticleId IdType="pii">S2352-1872(17)30028-1</ArticleId><ArticleId IdType="pmc">PMC5650647</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Clin Interv Aging. 2016 Feb 15;11:1-8</Citation><ArticleIdList><ArticleId IdType="pubmed">26929609</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Gastroenterol. 2008 Feb 12;8:5</Citation><ArticleIdList><ArticleId IdType="pubmed">18269746</ArticleId></ArticleIdList></Reference><Reference><Citation>Osteoporos Int. 2014 May;25(5):1617-23</Citation><ArticleIdList><ArticleId IdType="pubmed">24566586</ArticleId></ArticleIdList></Reference><Reference><Citation>Osteoporos Int. 2013 Jan;24(1):23-57</Citation><ArticleIdList><ArticleId IdType="pubmed">23079689</ArticleId></ArticleIdList></Reference><Reference><Citation>South Med J. 2009 May;102(5):486-92</Citation><ArticleIdList><ArticleId IdType="pubmed">19373149</ArticleId></ArticleIdList></Reference><Reference><Citation>J Midlife Health. 2013 Apr;4(2):107-26</Citation><ArticleIdList><ArticleId IdType="pubmed">24082708</ArticleId></ArticleIdList></Reference><Reference><Citation>Intern Med J. 2009 Mar;39(3):199-202</Citation><ArticleIdList><ArticleId IdType="pubmed">19383069</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurogastroenterol Motil. 2011 Jul;17(3):235-44</Citation><ArticleIdList><ArticleId IdType="pubmed">21860815</ArticleId></ArticleIdList></Reference><Reference><Citation>Indian J Endocrinol Metab. 2014 Jul;18(4):449-54</Citation><ArticleIdList><ArticleId IdType="pubmed">25143898</ArticleId></ArticleIdList></Reference><Reference><Citation>Korean J Intern Med. 2013 Nov;28(6):694-700</Citation><ArticleIdList><ArticleId IdType="pubmed">24307845</ArticleId></ArticleIdList></Reference><Reference><Citation>Osteoporos Int. 2007 Apr;18(4):553-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17120179</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinicoecon Outcomes Res. 2015 Nov 25;7:603-13</Citation><ArticleIdList><ArticleId IdType="pubmed">26648746</ArticleId></ArticleIdList></Reference><Reference><Citation>Bone Rep. 2015 Sep 12;3:61-66</Citation><ArticleIdList><ArticleId IdType="pubmed">28377968</ArticleId></ArticleIdList></Reference><Reference><Citation>Asia Pac J Clin Nutr. 2012;21(4):594-600</Citation><ArticleIdList><ArticleId IdType="pubmed">23017318</ArticleId></ArticleIdList></Reference><Reference><Citation>Consult Pharm. 2011 May;26(5):325-31</Citation><ArticleIdList><ArticleId IdType="pubmed">21733813</ArticleId></ArticleIdList></Reference><Reference><Citation>Bone. 2012 May;50(5):1039-47</Citation><ArticleIdList><ArticleId IdType="pubmed">22366398</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Interv Aging. 2009;4:357-65</Citation><ArticleIdList><ArticleId IdType="pubmed">19851511</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Orthop Surg. 2014 Mar;6(1):56-61</Citation><ArticleIdList><ArticleId IdType="pubmed">24605190</ArticleId></ArticleIdList></Reference><Reference><Citation>J Bone Miner Metab. 2012 May;30(3):359-66</Citation><ArticleIdList><ArticleId IdType="pubmed">22083905</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Osteoporos. 2012;7:193-200</Citation><ArticleIdList><ArticleId IdType="pubmed">23225297</ArticleId></ArticleIdList></Reference><Reference><Citation>J Bone Miner Res. 2004 Dec;19(12):1969-75</Citation><ArticleIdList><ArticleId IdType="pubmed">15537439</ArticleId></ArticleIdList></Reference><Reference><Citation>J Bone Metab. 2014 May;21(2):143-9</Citation><ArticleIdList><ArticleId IdType="pubmed">25006571</ArticleId></ArticleIdList></Reference><Reference><Citation>Aust Fam Physician. 2010 Oct;39(10):767-72</Citation><ArticleIdList><ArticleId IdType="pubmed">20890480</ArticleId></ArticleIdList></Reference><Reference><Citation>Patient Prefer Adherence. 2015 Jun 19;9:821-30</Citation><ArticleIdList><ArticleId IdType="pubmed">26150702</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Womens Health. 2013 Feb 14;13:7</Citation><ArticleIdList><ArticleId IdType="pubmed">23410131</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Osteoporos. 2016;11:19</Citation><ArticleIdList><ArticleId IdType="pubmed">27129487</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Australie</li><li>Corée du Sud</li><li>Inde</li><li>Taïwan</li><li>États-Unis</li></country><region><li>New Jersey</li><li>Région capitale de Séoul</li></region><settlement><li>Séoul</li></settlement></list><tree><country name="États-Unis"><region name="New Jersey"><name sortKey="Modi, A" sort="Modi, A" uniqKey="Modi A" first="A" last="Modi">A. Modi</name></region><name sortKey="Sajjan, S" sort="Sajjan, S" uniqKey="Sajjan S" first="S" last="Sajjan">S. Sajjan</name><name sortKey="Sen, S" sort="Sen, S" uniqKey="Sen S" first="S" last="Sen">S. Sen</name><name sortKey="Yang, X" sort="Yang, X" uniqKey="Yang X" first="X" last="Yang">X. Yang</name></country><country name="Australie"><noRegion><name sortKey="Ebeling, P R" sort="Ebeling, P R" uniqKey="Ebeling P" first="P R" last="Ebeling">P R Ebeling</name></noRegion><name sortKey="Baidya, S" sort="Baidya, S" uniqKey="Baidya S" first="S" last="Baidya">S. Baidya</name></country><country name="Taïwan"><noRegion><name sortKey="Lee, M S" sort="Lee, M S" uniqKey="Lee M" first="M S" last="Lee">M S Lee</name></noRegion></country><country name="Corée du Sud"><region name="Région capitale de Séoul"><name sortKey="Min, Y K" sort="Min, Y K" uniqKey="Min Y" first="Y K" last="Min">Y K Min</name></region></country><country name="Inde"><noRegion><name sortKey="Mithal, A" sort="Mithal, A" uniqKey="Mithal A" first="A" last="Mithal">A. Mithal</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SanteMusiqueV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A18 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000A18 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SanteMusiqueV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:29062864
|texte= Influence of gastrointestinal events on treatment of osteoporosis in Asia-Pacific women: Perspectives from physicians in the MUSIC OS-AP study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:29062864" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a SanteMusiqueV1
| This area was generated with Dilib version V0.6.38. |  |